Imunon Inc Stock Performance

IMNN Stock  USD 0.88  0.02  2.22%   
Imunon has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.28, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Imunon's returns are expected to increase less than the market. However, during the bear market, the loss of holding Imunon is expected to be smaller as well. Imunon Inc right now retains a risk of 3.99%. Please check out Imunon potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Imunon will be following its current trending patterns.

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Imunon Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Imunon may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor
1:15
Last Split Date
2022-03-01
1
Acquisition by Michael Tardugno of 12500 shares of Imunon at 0.8305 subject to Rule 16b-3
12/18/2024
2
Acquisition by Fritz Frederick J. of 2000 shares of Imunon at 4.686 subject to Rule 16b-3
01/17/2025
3
Imunon director Donald Braun acquires 29,480 worth of shares - MSN
01/30/2025
4
Acquisition by Braun Donald P of 2000 shares of Imunon at 1.32 subject to Rule 16b-3
01/31/2025
5
Insider Trading
02/18/2025
6
IMUNON Announces Translational Data from Phase 12 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
02/19/2025
7
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
02/20/2025
8
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
02/26/2025
9
Imunon Inc Q4 2024 Earnings Call Highlights Promising Advances Amid Financial Challenges
02/28/2025
10
Imunon, Inc. Earnings Call Clinical Success Amid Financial Challenges - TipRanks
03/03/2025
Begin Period Cash Flow5.8 M
  

Imunon Relative Risk vs. Return Landscape

If you would invest  84.00  in Imunon Inc on December 13, 2024 and sell it today you would earn a total of  4.00  from holding Imunon Inc or generate 4.76% return on investment over 90 days. Imunon Inc is currently generating 0.1534% in daily expected returns and assumes 3.9878% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Imunon, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Imunon is expected to generate 4.56 times more return on investment than the market. However, the company is 4.56 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.13 per unit of risk.

Imunon Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Imunon's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Imunon Inc, and traders can use it to determine the average amount a Imunon's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0385

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsIMNN
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.99
  actual daily
35
65% of assets are more volatile

Expected Return

 0.15
  actual daily
2
98% of assets have higher returns

Risk-Adjusted Return

 0.04
  actual daily
3
97% of assets perform better
Based on monthly moving average Imunon is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imunon by adding it to a well-diversified portfolio.

Imunon Fundamentals Growth

Imunon Stock prices reflect investors' perceptions of the future prospects and financial health of Imunon, and Imunon fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imunon Stock performance.

About Imunon Performance

By examining Imunon's fundamental ratios, stakeholders can obtain critical insights into Imunon's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Imunon is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 786.36  816.73 
Return On Tangible Assets-1.9 K-1.8 K
Return On Capital Employed 4.01  4.21 
Return On Assets-1.9 K-1.8 K
Return On Equity(4.39)(4.17)

Things to note about Imunon Inc performance evaluation

Checking the ongoing alerts about Imunon for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Imunon Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Imunon Inc has some characteristics of a very speculative penny stock
Imunon Inc had very high historical volatility over the last 90 days
Imunon Inc has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (18.62 B) with loss before overhead, payroll, taxes, and interest of (1.67 M).
Imunon Inc currently holds about 42.11 M in cash with (18.85 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Imunon Inc has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Bernards Rene of 5527 shares of Lixte Biotechnology at 2.51 subject to Rule 16b-3
Evaluating Imunon's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Imunon's stock performance include:
  • Analyzing Imunon's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imunon's stock is overvalued or undervalued compared to its peers.
  • Examining Imunon's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Imunon's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imunon's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Imunon's stock. These opinions can provide insight into Imunon's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Imunon's stock performance is not an exact science, and many factors can impact Imunon's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
0.014
Return On Assets
(0.76)
Return On Equity
(2.11)
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.